Gates Foundation commits $258.3 mn for malaria R&D with $100 mn for MMV

To develop effective, low-cost new antimalarial drugs

31 Oct 2005

“For far too long, malaria has been a forgotten epidemic,” said Bill Gates, co-founder of the Gates Foundation. “It’s a disgrace that the world has allowed malaria deaths to double in the last 20 years, when so much more could be done to stop the disease.”

The Bill & Melinda Gates Foundation today announced three grants totaling $258.3 million for advanced development of a malaria vaccine, new drugs, and innovative mosquito control methods to help defeat malaria, a disease that kills 2,000 African children every day.

The Medicines for Malaria Venture (MMV) will use its $100 million, five-year grant to work with public and private sector partners to develop new drugs that will be affordable and practical for use in poor countries.

“We’re racing the clock to develop effective, low-cost new antimalarial drugs,” said Dr Chris Hentschel, CEO of MMV. “Five years ago, the malaria drug research pipeline was virtually empty; now we’re developing 20 promising compounds, and six are already in clinical trials.”